Skip to content
Top Menu
July 21, 2026
  • Home
  • About ScandAsia
  • Advertisement rates
  • Contact us
Scandasia

Nordic News, Business and Life in Asia

  • Home
    • Home
    • What is ScandAsia?
    • Advertisement rates
    • ScandAsia Magazines
    • ScandAsia eNews
    • Thailand Expat Guide
    • Contact us
    • Privacy Policy – Users
  • Business in Asia
    • Business in Asia
    • Agriculture, fishing, forestry
    • Oil and Gas, Mining
    • Construction, infrastructure
    • Transportation, maritime
    • Energy
    • Manufacturing
    • Automotive
    • Food & Beverage
    • Textile
    • IT Telecom
    • Trading & Logistics
    • Banking, Fintech
    • Hospitality
    • Healthcare
    • Retail & Wholesale
    • Services
    • Education
    • Innovation & Technology
    • Entrepreneurship
    • Sustainability
  • ScandAsia News
    • China
    • Hong Kong
    • Thailand
    • Malaysia
    • Singapore
    • Indonesia
    • Philippines
    • Taiwan
    • Vietnam
    • Cambodia
    • Laos
    • Myanmar
    • Denmark
    • Sweden
    • Norway
    • Finland
    • Iceland
  • Living in Asia
    • Basic guides
    • Moving to Asia
    • Working in Asia
    • Studying in Asia
    • Doing things legally
    • Schools News
    • Home and Garden
    • Staying healthy
    • Traveling around
    • History & Heritage
      • ScandAsia magazines archive
  • ScandShop
    • Basket
    • Terms and Conditions
    • Privacy Policy – Shop
    • Data Protection Policy
    • Refund and Returns Policy
  • Opinion

Tag: Ozempic

Business in Asia / China / Denmark

Novo Nordisk says Ozempic copycats in China may be delayed

May 7, 2026 - by Alexander Vittrup - Leave a Comment

Danish pharmaceutical company Novo Nordisk said generic versions of its diabetes drug Ozempic could be delayed in China until 2027 due to regulatory data protection rights. The patent for semaglutide, …

Novo Nordisk says Ozempic copycats in China may be delayed Read More
Business in Asia / China / Denmark

Novo Nordisk tests China-developed drug for obesity and diabetes while competition is growing

March 26, 2026 - by Helene Sadjadi-Munk - Leave a Comment

The Danish pharmaceutical giant Novo Nordisk has reported encouraging results from a new diabetes and weight loss drug developed with a Chinese partner, Fierce Biotech reports. The candidate, known as …

Novo Nordisk tests China-developed drug for obesity and diabetes while competition is growing Read More
Business in Asia / China / Denmark / Healthcare

Novo Nordisk will lose patent protection on Saturday

March 20, 2026 - by Freja Nanna Mogensen - Leave a Comment

Novo Nordisk will lose patent protection for its blockbuster drug Ozempic in several major markets from Saturday. The patent expiry opens the door for other manufacturers to produce cheaper generic …

Novo Nordisk will lose patent protection on Saturday Read More
China / Denmark / General news

Novo Nordisk reports strong profits despite production constraints

November 7, 2024 - by Karoline Rosenkrantz Paasch - Leave a Comment

Novo Nordisk, the Danish pharmaceutical giant renowned for its diabetes and weight-loss medications, including the blockbuster drugs Ozempic and Wegovy, announced impressive third-quarter earnings despite challenges with production constraints. Novo …

Novo Nordisk reports strong profits despite production constraints Read More
Business in Asia / Denmark / Healthcare / Indonesia

Novo Nordisk will help combat diabetes in Indonesia

July 11, 2024 - by Lærke Kobberup - Leave a Comment

The Danish pharmaceutical company Novo Nordisk has signes a deal with a Indonesian state-owned drug company called Bio Farma. Their goal is to produce insulin to fight diabetes within Indonesia. …

Novo Nordisk will help combat diabetes in Indonesia Read More
Business in Asia / China / Denmark

Wegovy approved in China

June 25, 2024 - by Lærke Kobberup - Leave a Comment

The popular weight loss medicin Wegovy by the Danish phamaceutical firm Novo Nordisk has been approved for consumers in China. This has been confirmed by an employee at the company. …

Wegovy approved in China Read More
Business in Asia / China / Denmark / Healthcare

Chinese drugmaker seeks approval of Ozempic-like drug

April 4, 2024 - by Charlotte Nike Albrechtsen - Leave a Comment

A Chinese drugmaker applied for approval on 3 April 2024 to sell their biosimilar Ozempic drug in China. This potentially challenges the expansion plans of Novo Nordisk in China, who …

Chinese drugmaker seeks approval of Ozempic-like drug Read More
Business in Asia / China / Denmark / Healthcare

Approaching patent expiration in China may threaten Novo’s billion-dollar business

September 7, 2023September 20, 2023 - by Miabell Mallikka - Leave a Comment

Novo Nordisk has established itself in the medicine market with patents that earn billions. Mainly due to the obesity drug Wegovy and the diabetes medicine Ozempic. Both consists of an …

Approaching patent expiration in China may threaten Novo’s billion-dollar business Read More
Business in Asia / Denmark / Healthcare

Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company

September 3, 2023September 3, 2023 - by Miabell Mallikka - 1 Comment

Danish pharmaceutical company Novo Nordisk has surpassed LVMH and is now Europe’s most valuable listed company. LVMH, the world’s biggest luxury retailer, is currently suffering due to growing concerns about …

Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company Read More
Business in Asia / China / Denmark / Healthcare

Novo Nordisk’s diet drug may land in China soon

June 6, 2023 - by Miabell Mallikka - Leave a Comment

Danish pharmaceutical titan Novo Nordisk has applied to China’s drug regulator to widen the range of use of its diabetes medicine Ozempic. In the US Ozempic is also used as …

Novo Nordisk’s diet drug may land in China soon Read More

Posts pagination

1 2 Next

ScandAsia Recommends:

Scandasia Newsletter

Scandasia Magazine

ScandAsia July - August 2026

Thailand Expat Guide 2026

Thailand Expat Guide 2026

Latest 20 News Chronologically

IKEA puts eight Chinese stores up for sale

July 21, 2026

‘Save Lily’ parents accuse Sweden of illegally detaining daughter

July 21, 2026

Finnish design brand Marimekko opens floral pop-up in Bangkok

July 21, 2026

Thailand plans to buy eight more Swedish Gripen fighter jets

July 21, 2026

Finland grants visas to only 123 Thai berry pickers

July 21, 2026

Haaland campaign helps drive 31% rise in Norwegian salmon exports to China

July 20, 2026

EVFTA boosts Vietnam-Nordic trade as new EU rules raise the bar

July 20, 2026

Thai ambassador visits Bornholm to explore green energy cooperation

July 20, 2026

Laos charges distillery owner after methanol deaths of six foreign tourist

July 20, 2026

Swedish Atlas Copco buys Chinese heating and cooling company

July 17, 2026July 17, 2026

Malaysia now looks to make its own missiles after Norway deal fails

July 17, 2026

Norwegian suspect in Muay Thai trafficking case dead

July 17, 2026

Thailand launches billion-baht plan to boost tourism with cheaper hotels and flights

July 16, 2026

Norwegian sponser wanted in Muay Thai camp child abuse case

July 16, 2026

Chinese Embassy marks Communist Party anniversary with film screening in Copenhagen

July 16, 2026

Thailand’s tourism outlook weakens, while DTV enters a new phase

July 15, 2026

Video: Living with the danger beneath their feet

July 15, 2026July 15, 2026

Yanika and her family live with the danger of unexploded bombs beneath their home: “We just want to live a normal life”

July 15, 2026July 15, 2026

Hong Kong couple files UN complaint over Swedish custody case

July 15, 2026

Indonesia seeks stronger cybersecurity cooperation with Finland

July 15, 2026

Address

Scandinavian Publishing Co., Ltd.
211 Soi Prasert-Manukitch 29
Prasert-Manukitch Road
Bangkok 10230 – Thailand
Tel: +6629437166

Editor-in-chief: Gregers Moller
Email: [email protected]

Marketing Director: Finn Balslev
Email: [email protected]

Copyright © 2026 Scandasia.
Web by Webstudiet